Trial Profile
AML-BFM 2012: clinical trial for the treatment of acute myeloid leukemia in children and adolescents - an open prospective randomized phase III trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Etoposide (Primary) ; Cytarabine; Daunorubicin; Idarubicin; Methotrexate; Mitoxantrone; Prednisolone; Sorafenib; Tioguanine
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms AML-BFM 2012
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 19 Apr 2019 The trial has been discontinued in austria.
- 11 Apr 2017 Status changed from recruiting to completed.